

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

May 11, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai-400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Presentation to Analyst / Investor

In continuation to our letter dated April 30, 2026 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation to be made to Analyst / Investor.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a



CORONA Remedies Limited

Investor Presentation: May 2026



Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **CORONA Remedies Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness



Contents

Operational & Financial Performance

Financial & Operational Performance for Q4 and FY26

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies

Annexures

Management Team and Historical Financial Performance



Key Highlights for Q4 & FY26

Financial Highlights

Q4FY26 (Y-o-Y)

INR 353.1 Cr

+20.2%

FY26 (Y-o-Y)

INR 1,403.2 Cr

+17.3%

Return Ratios

FY26

40.8%

ROCE#

Key Highlights

- ✓ Reported healthy revenue **growth of 20.2% in Q4 and 17.3% in FY26** on a Y-o-Y basis, supported by brand strength and execution excellence.
- ✓ **Strategic Acquisition of Wokadine® (Ranked 2 in its segment)** from Dr. Reddy's from Internal Accruals, marks entry into **~Rs. 648¹ Crs** Povidone Iodine market.
- ✓ Acquired 7 brands from Bayers Zydus from Internal Accruals, to further Strengthening presence into infertility segment.
- ✓ **Bhayla facility received EAEU-GMP certification** in January 2026, enabling entry into five key Eurasian markets of Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan, unlocking market opportunity of up to **~USD 25 billion**
- ✓ Capacity expansion at the Bhayla facility to boost tablet and capsule production, adding **400 Mn units** to installed capacity
- ✓ Chronic and sub-chronic therapies continued to perform well, **contributing ~72.3% & 71.9% of total Revenue** in Q4FY26 and FY26 respectively

REVENUE

INR 62.0 Cr

+14.4%

17.6% EBITDA Margin (-89 bps)

INR 293.4 Cr

+22.3%

20.9% EBITDA Margin (+85 bps)

29.2%

ROE#

INR 45.3 Cr

+43.7%

12.8% PAT Margin (+210 bps)

INR 199.4 Cr*

+33.4%

14.2% PAT Margin (+172 bps)

78.2%

OCF/EBITDA

Adj. PAT

* Excludes one-time statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) in FY26

ROE and ROCE for FY26 excludes one-time statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr)

¹Pharmatrac Feb '26

Consolidated Profit & Loss Statement



Profit and Loss (INR Crores)	Q4FY26	Q4FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	353.1	293.7	20.2%	1,403.2	1,196.4	17.3%
Cost of Goods Sold	66.2	56.9		260.9	236.5	
Gross Profit	286.9	236.8		1,142.2	959.9	
Gross Margin (%)	81.2%	80.6%		81.4%	80.2%	
Employee Cost	106.6	84.9		403.0	346.1	
Other Expenses	118.2	97.8		445.8	373.8	
EBITDA	62.0	54.2	14.4%	293.4	240.0	22.3%
EBITDA Margin (%)	17.6%	18.5%	-80 BPS	20.9%	20.1%	80 BPS
Depreciation & Amortization	10.3	10.0		37.9	37.2	
Other Income	4.1	1.4		10.7	5.9	
EBIT	55.8	45.6		266.2	208.8	
Finance Cost	1.4	2.2		7.0	10.6	
Share in Profit/(loss) in Associate	0.3	0.2		0.3	0.4	
Profit before tax (before exceptional items)	54.7	43.6		259.5	198.5	
Exceptional Income/(Expense)*	0.0	0.0		-19.1	0.0	
Profit before tax (after exceptional items)	54.7	43.6		240.4	198.5	
Tax Expense	9.4	12.1		55.3	49.1	
Reported Profit After Tax	45.3	31.5	43.7%	185.1	149.4	23.9%
Add: Adjustment for exceptional items (net of tax)*	0.0	0.0		14.3	0.0	
Adjusted Profit After Tax*	45.3	31.5	43.7%	199.4	149.4	33.4%
Adjusted Profit After Tax Margin (%)	12.8%	10.7%	210 BPS	14.2%	12.5%	170 BPS

* Excludes one-time statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) in FY26



Consolidated Balance Sheet

Assets (INR Crores)	Mar-26	Mar-25
Non - Current Assets	856.8	591.0
Property, plant and equipment	291.1	198.7
Capital work-in-progress	143.1	186.0
Intangible assets	262.8	171.2
Investments accounted as per equity method	26.1	25.9
Financial Assets		
Investments	0.2	0.1
Other Financial Assets	129.9	1.3
Loans	0.0	0.0
Other non-current assets	3.6	7.9
Current Assets	348.3	338.9
Inventories	125.0	129.5
Financial Assets		
(i) Trade receivables	145.6	118.3
(ii) Cash and cash equivalents	1.8	3.2
(iii) Bank balances	42.3	66.1
Loans	0.3	0.4
Other Financial Assets	0.3	2.6
Other Current Assets	33.1	18.8
Total Assets	1,205.1	929.9

Equity & Liabilities (INR Crores)	Mar-26	Mar-25
Total Equity	746.9	606.3
Share Capital	61.2	61.2
Other Equity	685.7	545.2
Non-Current Liabilities	97.1	83.9
Financial Liabilities		
(i) Borrowings	0.0	16.0
Provisions	66.1	38.6
Deferred tax liabilities (net)	12.2	8.3
Lease Liabilities	18.9	21.0
Current Liabilities	361.2	239.6
Financial Liabilities		
(i) Borrowings	142.9	46.7
(ii) Trade Payables	147.1	143.5
(iii) Other Financial Liabilities	19.7	4.8
Other Current Liabilities	7.0	8.4
Lease Liabilities	3.1	2.5
Current Tax Liabilities	8.4	6.3
Provisions	33.0	27.4
Total Equity & Liabilities	1,205.1	929.9

*Borrowings includes Overdraft against Fixed Deposit. Fixed Deposits shown under Other Financial Assets. As on Mar-26 company is Net cash company

Abridged Consolidated Cash Flow Statement



Particulars (INR Crores)	FY26	FY25
Profit Before Tax	240.4	198.5
Adjustments for: Non - Cash Items / Other Investment or Financial Items	44.4	52.3
Operating profit before working capital changes	284.8	250.8
Changes in working capital	-5.9	-17.1
Cash generated from Operations	278.9	233.8
Income taxes paid (net)	-49.4	-43.3
Net Cash from Operating Activities	229.5	190.5
Net Cash from Investing Activities	-256.1	-83.9
Net Cash from Financing Activities	25.3	-106.6
Net Increase/(Decrease) in Cash and Cash equivalents	-1.4	0.1
Add: Cash & Cash equivalents at the beginning of the year	3.2	3.2
Cash & Cash equivalents at the end of the year	1.8	3.2



Contents

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies

Operational & Financial Performance

Financial & Operational Performance for Q4 and FY26

Annexures

Management Team and Historical Financial Performance

CORONA's 3C Philosophy



Culture

- Ruthless Execution
- Internal Promotion
- Adaptability
- Humbleness

Courage


- Accepting Mistakes and improving
- Robust Inorganic Opportunities

Commitment

- Global Quality Products
- Value Creation for Stakeholders
- Long Term Sustainable Growth



Journey over the years






CORONA Remedies at a Glance

17.3%
Revenue growth ¹

2.0x growth compared to IPM ¹



Jumped 5 ranks in 3 years

Over MAT Mar-23 to MAT Mar-26




95.9%

Revenue from India Business for FY26




71.9%

Chronic portfolio contribution for FY26




76 Brands with **32** Engines Brands



#5 in Women's Healthcare
#5 in Pain Management
#9 in Urology
#20 in Cardio-Diabeto



EU-GMP, EAEU-GMP & WHO-GMP approved Gujarat facility
WHO-GMP approved Himachal Pradesh facility



Strategic acquisition of Brands from Bayer & Dr. Reddy's Laboratories from Internal accruals



Source: Pharmatrac
Notes: [1] By Domestic Sales between MAT Mar-25 and MAT Mar-26 | [2] Ranking under each therapy as on MAT Mar-26 in addressable market



CORONA's Competitive Edge Lies in Execution Excellence



Fastest Growing in Indian Pharmaceutical Market (IPM)

17.2% Revenue MAT Growth— Fastest Growth Among Top 30 Indian Pharma Peers, **Climbing 5 Ranks** in 3 Years*

Market Share Gains & New Launches

Consistently delivering **volume growth** with market share gain, new product launches, geographical expansion and field force expansion

Ability to Create & Scale Brands

Demonstrated track record of **building prescriber-trusted brands** across chronic and sub-chronic segments

Well-Diversified Brand Portfolio[#]

Top 10 brands account for 50.4% of revenue, ensuring **diversified and sustainable growth**

Middle of the Pyramid Approach


Focus on specialist doctors with marketing and distribution in urban and semi-urban markets with higher prescription growth

Strategic shift to chronic & sub-chronic segment[#]


Shifted **Portfolio Mix from 70:30 to 28:72** (Acute:Chronic) from FY 2013 to FY 2026; Driving Higher Customer Stickiness and Margin Expansion

*PharmaTrac Mar-26
Internal Data

Quality Focused State of the Art Manufacturing Facilities



Total Installed Capacity



*Includes additional commercial production of 400 Mn tablets commenced on 22nd December 2025 at the Gujarat Facility



Contents

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies

Operational & Financial Performance


Financial & Operational Performance for Q4 and FY26

Annexures


Management Team and Historical Financial Performance

Indian Pharmaceutical Market : High-Growth Landscape

IPM is poised to grow at CAGR of 8-9% till FY30



With growth in chronic segment expected to outpace acute segment




Growth drivers for domestic formulations industry






CORONA Remedies: Demonstrated 2.0x Growth compared to IPM

CORONA has grown at 2.0x compared to IPM growth [1]



Growth driven by volume, price and new product launches






Rank Progression – Jumped 1 Rank in last one year



Source: Pharmatrac

[1] By domestic sales between MAT Mar-25 and MAT Mar-26; [2] NI – New Introductions:

Cementing position in Chronic segment with focus on four Key Therapies




Source: Pharmatrac

[1] By domestic sales between MAT Mar-25 and MAT Mar-26; [2] As of MAT Mar-26 in addressable market;

Focussed presence in the “Middle of the Pyramid” segment



Specialty-wise prescription split



Strategic focus on specialist and super-specialist doctors in the 'middle of the pyramid'; resulting in a higher prescription contribution compared with IPM

Source : CRISIL Intelligence
 ^Other specialist includes categories (therapies) where CORONA has no presence/limited presence



Contents

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies

Operational & Financial Performance

Financial & Operational Performance for Q4 and FY26

Annexures

Management Team and Historical Financial Performance

“Engine” Brands approach with Successful Scaling Up of Brands

32 Engine Brands


~76%
Contribution to Domestic Sales
over MAT Mar-23 to MAT Mar-26

~19%
CAGR over
MAT Mar-23 to MAT Mar-26

Top 5 Brands

Brand	Therapy
B-29	VMN
Myoril	Pain / Analgesics
Tricium	Gynaecology
Cortel	Cardiac
Obimet	Anti-Diabetic

Established track record of building and scaling brands





Acquisition & Strategic Collaborations for India Business

Significantly scaled-up acquired brands

Sr. No	Acquired From	Brands
1	GSK Pharmaceuticals Limited	Dilo
	Glaxo Group Limited	Stelbid
		Vitneurin
2	ABBOTT India Limited	Thyrocab
		Obimet
3	Sanofi Healthcare India Private Limited	Myoril
4	Bayer Zydus Pharma Private Limited	7 Distinct Brands
5	Dr. Reddy's Laboratories Limited	Wokadine

Strategic collaborations for India Business

Ferring Pharmaceuticals, Switzerland


In-Licensing Arrangement for certain products in Women's Healthcare and Urology therapies

La Chandra Pharmalabs Private Limited


Investment in La Chandra Pharmalabs for **backward integration** of Hormone API manufacturing

Strategic Portfolio Diversification & Brand Development

Chronic v/s Acute




10 Years




Chronic
Acute

Accelerating growth in chronic therapies - Outperforming the IPM

Therapy Wise




10 Years




Womens Healthcare
Pain Management
Cardio Diabeto
Urology
Others

Strengthening focus on core therapies and exploring opportunities to broaden the therapy portfolio

Geography Wise



10 Years



West
North
South
East

Expanding and diversifying geographical presence to strengthen and deepen pan-India penetration

Source: Internal Data



Contents

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies


Operational & Financial Performance

Financial & Operational Performance for Q4 and FY26

Annexures

Management Team and Historical Financial Performance

CORONA Remedies Limited





Contents

About us

Overview of CORONA

CORONA: Outpacing IPM Growth

CORONA vs. IPM

Focused Brand Building Approach

Strong brand recall across Therapeutic Areas

Road Ahead

Key Growth Strategies

Operational & Financial Performance

Financial & Operational Performance for Q4 and FY26

Annexures

Management Team & Historical Financial Performance

Professional Senior Management Leading the Way



Niravkumar Kritikumar Mehta
Managing Director & CEO

Over 2 decades of experience in the pharmaceutical industry.



Ankur Kritikumar Mehta
Joint Managing Director

Over 2 decades of experience in the pharmaceutical industry.



Viral Bhupendrabhai Sitwala
Whole-Time Director

Over 2 decades of experience in the pharmaceutical industry.



Bhavin Naresh Bhagat
Chief Financial Officer

A Chartered Accountant by profession. Has over 2 decades of experience in the finance & pharmaceutical industry



Bhaven Shah
President - Commercial

Over 3 decades of experience. Oversees supply chain operations, production planning, and warehouse management.



Vijay Charlu
President – India Business

Over 3 decades of experience. Leads sales and marketing activities and manages product portfolio and regulatory compliance in India.



Sangeeta Thaker
President – Global Business

Over 2 decades of experience. Handles global marketing, product planning, and compliance.



Tejas Kothari
Vice President – Corp. Strategy & Business Development

Over 2 decades of experience. Handles strategic planning, business development, and acquisitions.



Chetna Prabhatkumar Dharajiya
CS & Compliance Officer

15+ years of experience. Handles secretarial work and statutory compliances.



Experienced Board of Directors



Niravkumar Kritikumar Mehta
Managing Director & CEO



Ankur Kritikumar Mehta
Joint Managing Director



Viral Bhupendrabhai Sitwala
Whole-Time Director



Dr. Kiritkumar Laxmidas Mehta
Chairman and Non-Executive Director



Ameetkumar Hiranyakumar Desai
Independent Director

Has over 3 decades of experience across sectors like pharmaceuticals, defence and finance.



Monica Kanuga
Independent Director

Has over 3 decades of experience in corporate compliance and governance



Shirish Gundopant Belapure
Independent Director

Has over 3 decades of experience in building quality state of the art manufacturing facilities in pharmaceutical industry



Bhaskar Vemban Iyer
Independent Director

Has over 3 decades of experience across domestic formulation pharmaceutical business

ESG @ CORONA Remedies



E

- Existing solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park Spread across 11.9 Acres which saves significant electricity cost
- Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearing un-ironed clothes
- Effluent Treatment plant (ETP) at Bhayla Plant for achieving zero liquid discharge.



S

- Financial Assistance to Young Talent for promotion of Sports and Education.
- Blood donation camps organized at HO and manufacturing facilities.
- Investing in Employee training increased by 50%
- Promoting Gender Equality. 40% of the total workforce at Solan Plant are female employees.



G

- The World Bank Group awarded the Company with EDGE Advance Certificate recognizing the Company for energy and water saving measures.
- A+ Credit Rating
- EU-GMP Certified Plant. One World One Quality.
- Serialization and QR Code Technology for product counterfeiting on the strip



Historical Consolidated Profit & Loss Statement

Profit and Loss (INR Crores)	FY26	FY25	FY24	FY23
Revenue from Operations	1,403.2	1,196.4	1,014.5	884.1
Cost of Goods Sold	260.9	236.5	226.8	211.0
Gross Profit	1,142.2	959.9	787.6	673.1
Gross Margin (%)	81.4%	80.2%	77.6%	76.1%
Employee Cost	403.0	346.1	295.4	254.8
Other Expenses	445.8	373.8	337.5	290.3
EBITDA	293.4	240.0	154.7	128.0
EBITDA Margin (%)	20.9%	20.1%	15.3%	14.5%
Depreciation & Amortization	37.9	37.2	28.3	20.1
Other Income	10.7	5.9	6.5	7.1
EBIT	266.2	208.8	132.9	114.9
Finance Cost	7.0	10.6	14.4	4.3
Share in Profit/(loss) in Associate	0.3	0.4	0.0	0.2
Profit before tax (before exceptional items)	259.5	198.5	118.5	110.9
Exceptional Income/(Expense)*	-19.1	0.0	0.0	0.0
Profit before tax (after exceptional items)	240.4	198.5	118.5	110.9
Tax Expense	55.3	49.1	28.0	26.0
Reported Profit After Tax	185.1	149.4	90.5	84.9
Add: Adjustment for exceptional items (net of tax)*	14.3	0.0	0.0	0.0
Adjusted Profit After Tax *	199.4	149.4	90.5	84.9
Adjusted Profit After Tax Margin (%)	14.2%	12.5%	8.9%	9.6%

* Excludes one-time statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) in FY26



Historical Consolidated Balance Sheet

Assets (INR Crores)	Mar-26	Mar-25	Mar-24	Mar-23
Non - Current Assets	856.8	591.0	540.7	303.5
Property, plant and equipment	291.1	198.7	191.0	184.1
Capital work-in-progress	143.1	186.0	120.6	64.7
Intangible assets	262.8	171.2	192.7	0.5
Investments accounted as per equity method	26.1	25.9	25.5	25.5
Financial Assets				
Investments	0.2	0.1	0.1	0.1
Other Financial Assets	129.9	1.3	3.2	15.8
Deferred tax assets (net)	0.0	0.0	0.0	4.3
Loans	0.0	0.0	0.1	0.0
Other non-current assets	3.6	7.9	7.5	8.6
Current Assets	348.3	338.9	289.9	291.5
Inventories	125.0	129.5	98.3	105.4
Investments	0.0	0.0	0.0	6.0
Financial Assets				
(i) Trade receivables	145.6	118.3	99.9	87.0
(ii) Cash and cash equivalents	1.8	3.2	3.2	14.5
(iii) Bank balances	42.3	66.1	66.7	62.2
Loans	0.3	0.4	0.4	0.4
Other Financial Assets	0.3	2.6	0.0	0.0
Other Current Assets	33.1	18.8	21.4	16.0
Total Assets	1,205.1	929.9	830.6	595.0

Equity & Liabilities (INR Crores)	Mar-26	Mar-25	Mar-24	Mar-23
Total Equity	746.9	606.3	480.4	408.5
Share Capital	61.2	61.2	61.2	61.2
Other Equity	685.7	545.2	419.2	347.4
Non-Current Liabilities	97.1	83.9	126.0	49.1
Financial Liabilities				
(i) Borrowings	0.0	16.0	67.0	0.0
Provisions	66.1	38.6	32.0	24.8
Deferred tax liabilities (net)	12.2	8.3	4.3	0.0
Other Financial Liabilities	0.0	0.0	0.0	0.5
Lease Liabilities	18.9	21.0	22.6	23.8
Current Liabilities	361.2	239.6	224.2	137.4
Financial Liabilities				
(i) Borrowings	142.9	46.7	67.1	2.3
(ii) Trade Payables	147.1	143.5	114.3	94.4
(iii) Other Financial Liabilities	19.7	4.8	5.4	8.0
Other Current Liabilities	7.0	8.4	6.8	8.6
Lease Liabilities	3.1	2.5	2.2	18.4
Current Tax Liabilities	8.4	6.3	4.8	3.8
Provisions	33.0	27.4	23.5	1.8
Total Equity & Liabilities	1,205.1	929.9	830.6	595.0


Historical Consolidated Abridged Cash Flow Statement



Abridged Cash Flow Statement (INR Crores)	FY26	FY25	FY24	FY23
Net Profit Before Tax	240.4	198.5	118.5	110.9
Adjustments for: Non - Cash Items / Other Investment or Financial Items	44.4	52.3	46.9	22.6
Operating profit before working capital changes	284.8	250.8	165.3	133.4
Changes in working capital	-5.9	-17.1	9.3	-4.9
Cash generated from Operations	278.9	233.8	174.7	128.5
Direct taxes paid (net of refund)	-49.4	-43.3	17.9	25.8
Net Cash from Operating Activities	229.5	190.5	156.8	102.7
Net Cash from Investing Activities	-256.1	-83.9	-266.6	-50.2
Net Cash from Financing Activities	25.3	-106.6	98.5	-44.7
Net Increase/(Decrease) in Cash and Cash equivalents	-1.4	0.1	-11.3	7.7
Add: Cash & Cash equivalents at the beginning of the year	3.2	3.2	14.5	6.8
Cash & Cash equivalents at the end of the year	1.8	3.2	3.2	14.5







Historical Financial Statement



*Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) for FY26



Historical Financial Ratios



*ROE and ROCE for FY26 is annualised & Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr)



THANK YOU

For further information, please contact:

CORONA Remedies Limited

CIN: L24231GJ2004PLC044656

Ms. Chetna Dharajiya – Company Secretary & Compliance Officer

investor@coronaremedies.com

Strategic Growth Advisors Private Limited (SGA)

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah

sagar.shroff@sgapl.net / tanay.shah@sgapl.net

+91 98205 19303 / +91 98333 91899